Ozmosi | 9MW0311 Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

9MW0311

Alternative Names: 9MW0311
Clinical Status: Active
Latest Update: 2025-09-05
Latest Update Note: News Article

Product Description

Mechanisms of Action: TNFSF11 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Injection

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Mabwell Therapeutics
Company Location: Asia Pacific
Company Founding Year: 2017
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 9MW0311

Countries in Clinic: China

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Osteoporosis, Postmenopausal

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06804590

9MW0311-2024-CP302

P3

Recruiting

Osteoporosis, Postmenopausal

2026-04-30

21%

2025-02-07

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title

09/05/2025

News Article

Mabwell Secures Pakistan's First Denosumab Injection Approval